全外显子组测序可评估同源重组缺陷以识别PARPi敏感性卵巢肿瘤
本研究基于全外显子组测序(WES)评估基因组杂合性缺失(gLOH)、大片段状态转换(LST)和BRCA突变,构建基因组瘢痕评分(GSS)及综合HRD评分,并与标准检测方法比较。WES与OncoScan CNV及Myriad MyChoice检测的LOH值和GSS值高度一致;在1661例PARPi治疗的卵巢癌患者中,GSS高且BRCA1/2突变组中位总生存50.8个月,GSS高且BRCA1/2野生型组42.7个月,GSS低且BRCA1/2野生型组36.6个月,各组间差异显著。
要点
- WES检测的LOH值和GSS值与OncoScan CNV及Myriad MyChoice检测高度一致。
- GSS高且BRCA1/2突变组中位OS为50.8个月,GSS高且BRCA1/2野生型组为42.7个月。
- GSS低且BRCA1/2野生型组中位OS为36.6个月,各组间差异显著。
核心结论
- 基于WES评估BRCA结果并结合gLOH和LST的GSS方法所构建的HRD检测可预测PARPi治疗反应。
研究设计与样本
- 本研究使用WES评估gLOH、LST和BRCA突变,并与标准检测方法比较。
- 基于gLOH和LST组合构建优化的基因组瘢痕评分(GSS),再结合GSS与BRCA状态构建综合HRD评分。
- 查询1661例接受PARPi治疗的卵巢癌患者的生存数据以优化与PARPi反应相关的GSS和HRD评分。
主要发现
- WES结果与OncoScan CNV检测的LOH值及Myriad MyChoice检测的GSS值分别显示高度一致。
- PARPi治疗患者中位总生存:GSS高且BRCA1/2突变组为50.8个月,GSS高且BRCA1/2野生型组为42.7个月,GSS低且BRCA1/2野生型组为36.6个月,各组间差异显著。
- 合并BRCA1/2突变和野生型GSS高组后中位OS为47.8个月,显著高于GSS低且BRCA1/2野生型组。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND/OBJECTIVES: Homologous recombination repair deficiency (HRD) is frequently detected in gynecological cancers and is associated with sensitivity to poly-ADP ribose polymerase inhibition (PARPi). BRCA1/2 mutations have been approved as biomarkers for PARPi therapy, along with genomic patterns such as genomic loss of heterozygosity (gLOH) and large-scale transitions (LSTs). Clinical applications of various HRD assays are still under investigation. Here we validate the performance of a novel HRD assay based on whole-exome sequencing (WES). METHODS: WES was used to evaluate gLOH, LST, and BRCA mutations and this data was compared to standard assays. An optimized genomic scar score (GSS) was based on combined gLOH and LST. A comprehensive HRD score was then developed, combining GSS and BRCA status. Survival data from 1661 PARPi-treated ovarian cancer patients was queried to optimize GSS and HRD scores associated with PARPi response. RESULTS: A comparison of WES results to the OncoScan CNV assay and Myriad MyChoice assay showed high concordance for LOH values and GSS values, respectively. Median overall survival in PARPi-treated patients was 50.8 months for GSS-high, BRCA1/2-mut, 42.7 months for GSS-high, BRCA1/2-WT, and 36.6 months for GSS-low, BRCA1/2-WT patients with significant differences between each group. Combining the BRCA1/2-mut and WT GSS-high groups resulted in a median OS value of 47.8 months, significantly higher than the GSS-low BRCA1/2-WT group. CONCLUSIONS: The use of a WES assay to assess BRCA results, along with a GSS method incorporating gLOH and LST, produced a HRD test that is predictive for PARPi therapy.
引用
- Evans E, Dholakia J, Abraham J, et al. Whole-exome sequencing provides assessment of homologous recombination deficiency for identification of PARPi-responsive ovarian tumors. Gynecol Oncol. 2025. PMID: 40344964. doi:10.1016/j.ygyno.2025.04.586
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。